In the past 5–10 years there has been a growing trend for substituting conventional 5-fluorouracil with the oral prodrug of 5-fluorouracil, capecitabine, in chemotherapy regimens. This regimen ...

Novel HER2 therapies show strong intracranial efficacy, enabling systemic treatment over local therapy for small, ...

In a clinical practice guideline issued by the American Society for Radiation Oncology and published online Feb. 27 in ...

Interim results from three trials exploring the use of Alpha DaRT® in treating pancreatic cancer showing high disease control rate, impressive ...

Sorafenib, in combination with capecitabine, had a statistically significant improvement in the median progression-free survival and time-to-progression in comparison with capecitabine/placebo for ...

Interim results from three trials exploring the use of Alpha DaRT® in treating pancreatic cancer showing high disease control rate, impressive overall survival in sub-group analyses, and positive safe ...

For 1 week, she had experienced confusion, nausea and frequent urination. Preceding this, she had completed seven cycles of capecitabine chemotherapy for her breast cancer. She did not have a history ...

Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: Phase II study evaluating the activity of 177 Lu-Octreotate peptide receptor radionuclide therapy (LuTate PRRT) and capecitabine, ...

If a person carries a mutation(s) in the DPYD gene, certain chemotherapies (fluorouracil (5-FU) or capecitabine (Xeloda or ...

Camizestrant with a CDK 4/6 inhibitor had a statistically significant and clinically meaningful improvement in PFS in HR+/HER2– advanced breast cancer. Dr. Debu Tripathy breaks down the FDA approval ...

After hours: March 10 at 5:16:24 PM EDT Loading Chart for PBYI ...